Proposal for the management of COVID-19-associated coagulopathy in children

Area of Science:

• Infectious Diseases
• Hematology
• Pediatrics

Background:

• COVID-19 pandemic presents a significant mortality rate, particularly in adults.
• A novel coagulopathy is a primary cause of death in severely ill COVID-19 patients.
• Similar coagulopathic phenomena are increasingly recognized in pediatric COVID-19 cases.

Purpose of the Study:

• To review and synthesize current evidence on anticoagulant treatment for COVID-19 in children.
• To develop practical recommendations for implementing anticoagulant therapy in pediatric COVID-19 patients.
• To address the challenges and complexities of pediatric anticoagulant use in the context of evolving scientific literature.

Main Methods:

• Extensive literature review of published studies on COVID-19 and coagulopathy.
• Analysis of evidence regarding anticoagulant efficacy and safety in pediatric populations.
• Consideration of resource availability in Mexico for treatment implementation.

Main Results:

• Anticoagulant therapy is a cornerstone in managing COVID-19, especially with associated coagulopathy.
• Pediatric COVID-19 patients may also develop coagulopathy, requiring careful consideration for anticoagulation.
• Evidence on pediatric anticoagulation is rapidly evolving, often complex and contradictory.

Conclusions:

• A structured approach to anticoagulant treatment is crucial for pediatric COVID-19 patients.
• Recommendations are provided to guide clinicians in Mexico, considering local resources.
• Further research is needed to refine pediatric anticoagulant strategies for COVID-19.